ID | 53005 |
フルテキストURL | |
著者 |
Yasugi, Masayuki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Takigawa, Nagio
Kawasaki Hosp, Kawasaki Med Sch, Dept Gen Internal Med 4
Ochi, Nobuaki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Ohashi, Kadoaki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
ORCID
Kaken ID
researchmap
Harada, Daijiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Ninomiya, Takashi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Murakami, Toshi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Honda, Yoshihiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Ichihara, Eiki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Tanimoto, Mitsune
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
Kaken ID
publons
researchmap
Kiura, Katsuyuki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med
ORCID
Kaken ID
publons
researchmap
|
抄録 | Everolimus is an orally administered mTOR inhibitor. The effect, and mechanism of action, of everolimus on lung cancers with an epidermal growth factor receptor (EGFR) mutation remain unclear. Four gefitinib-sensitive and -resistant cell lines were used in the present work. Growth inhibition was determined using the MTT assay. Transgenic mice carrying the EGFR L858R mutation were treated with everolimus (10 mg/kg/day), or vehicle alone, from 5 to 20 weeks of age, and were then sacrificed. To evaluate the efficacy of everolimus in prolonging survival, everolimus (10 mg/kg/day) or vehicle was administered from 5 weeks of age. The four cell lines were similarly sensitive to everolimus. Expression of phosphorylated (p) mTOR and pS6 were suppressed upon treatment with everolimus in vitro, whereas the pAKT level increased. The numbers of lung tumors with a long axis exceeding 1 mm in the everolimus-treated and control groups were 1.9 +/- 0.9 and 9.4 +/- 3.2 (t-test, p<0.001), respectively. pS6 was suppressed during everolimus treatment. Although apoptosis and autophagy were not induced in everolimus-treated EGFR transgenic mice, angiogenesis was suppressed. The median survival time in the everolimus-treated group (58.0 weeks) was significantly longer than that in the control group (31.2 weeks) (logrank test, p<0.001). These findings suggest that everolimus had an indirect effect on tumor formation by inhibiting angiogenesis and might be effective to treat lung tumors induced by an activating EGFR gene mutation.
|
キーワード | Non-small cell lung cancer
Adenocarcinoma
Everolimus
mTOR
EGFR
|
発行日 | 2014-08-15
|
出版物タイトル |
Experimental Cell Research
|
巻 | 326巻
|
号 | 2号
|
開始ページ | 201
|
終了ページ | 209
|
ISSN | 0014-4827
|
資料タイプ |
学術雑誌論文
|
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/52961
|
言語 |
英語
|
著作権者 | (c) 2014 Elsevier Inc. All rights reserved.
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
Web of Science KeyUT |